Vascular Dynamics, Inc.

Vascular Dynamics, Inc. develops advanced medical devices aimed at optimizing cardiovascular health management by leveraging innovative catheter-based technologies to address vascular diseases such as hypertension. Founded in 2008, Vascular Dynamics, Inc. specializes in developing medical devices for cardiovascular health.

The company is headquartered in Mountain View, US. In July 2022, Vascular Dynamics raised USD 20. 00 mn in a Series D funding round led by Rainbow Medical Ltd. and joined by HBM Partners and Invus, bringing the total amount raised to USD 20.

00 mn with a current company valuation of USD 50. 81 mn. Vascular Dynamics specializes in innovative medical devices designed to enhance the management of cardiovascular health. Their flagship product is a catheter system that facilitates real-time monitoring and treatment of vascular diseases, particularly resistant hypertension.

The technology, which has been clinically validated, is targeted towards healthcare providers, hospitals, and specialized clinics across North America and Europe. The company focuses on both urban and rural healthcare markets, effectively reaching areas with limited access to advanced cardiac care. Revenue for Vascular Dynamics is generated primarily through the direct sales of its medical devices to healthcare institutions and professionals. The company employs a pricing model that typically includes direct purchases and may offer volume-based discounts for larger healthcare systems.

Each device sold is supported by a comprehensive training program for medical staff, ensuring effective application and improved patient outcomes. Vascular Dynamics plans to utilize the USD 20. 00 mn raised in July 2022 to further develop its product range and expand into new markets. The company is focusing on enhancing its existing catheter systems and launching additional innovative products to serve healthcare providers more effectively.

They aim to enter new geographic regions by 2024, specifically targeting markets in Asia and South America to provide advanced cardiovascular treatments.